Insider · CIK 0001950499

Blume-Jensen Peter

Reports to the SEC for 1 company · WATERTOWN, MA

sec.gov

Transactions

Companies

Filings

CIK

0001950499

Forms 4 and 5

Insider transactions

47 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-25	ACRVAcrivon Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−14K sh	$2.21	−$31K	2,230,052
2026-08-18	ACRVAcrivon Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−1,229 sh	$2.01	−$2,470.29	2,244,088
2026-08-18	ACRVAcrivon Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−484 sh	$2.01	−$972.84	385,859
2026-05-21	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−13.7K sh	$1.79	−$24.6K	2,245,317
2026-05-18	ACRVAcrivon Therapeutics, Inc.A Award	Director, President and CEO	AAward	+72.7K sh	—	—	386,343
2026-05-18	ACRVAcrivon Therapeutics, Inc.A Award	Director, President and CEO	AAward	+180K sh	—	—	2,259,046
2026-05-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−1,253 sh	$1.92	−$2,405.76	2,078,951
2026-05-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−490 sh	$1.92	−$940.8	313,637
2026-03-01	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+185K sh	—	—	185,495
2026-03-01	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+417K sh	—	—	417,210
2026-02-21	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−14.3K sh	$1.53	−$21.8K	2,080,204
2026-02-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−579 sh	$1.63	−$943.77	314,127
2026-02-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−1,302 sh	$1.63	−$2,122.26	2,094,469
2026-01-14	ACRVAcrivon Therapeutics, Inc.P Purchase	Director, President and CEO	PPurchase	+49K sh	$1.68	+$82.1K	2,095,771
2025-11-21	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−19.9K sh	$2.30	−$45.8K	2,046,771
2025-11-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−59.8K sh	$2.24	−$134K	2,066,675
2025-11-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−490 sh	$2.24	−$1,097.6	314,706
2025-08-21	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−19.9K sh	$1.32	−$26.3K	2,126,440
2025-08-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−59.8K sh	$1.39	−$83.1K	2,146,345
2025-08-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−490 sh	$1.39	−$681.1	315,196
2025-05-21	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−19.9K sh	$1.15	−$22.9K	2,206,111
2025-05-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−59.8K sh	$1.14	−$68.1K	2,226,015
2025-05-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−491 sh	$1.14	−$559.74	315,686
2025-03-01	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+390K sh	—	—	390,390
2025-03-01	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+141K sh	—	—	140,540
2025-02-21	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−19.9K sh	$5.54	−$110K	2,285,781
2025-02-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−37.2K sh	$5.42	−$201K	2,305,685
2025-02-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−579 sh	$5.42	−$3,138.18	316,177
2024-11-21	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−19.9K sh	$6.44	−$128K	2,342,837
2024-11-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−59.8K sh	$7.92	−$473K	2,362,747
2024-11-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−490 sh	$7.92	−$3,880.8	316,756
2024-08-21	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−79.6K sh	$9.19	−$732K	2,422,513
2024-08-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−59.8K sh	$7.02	−$420K	2,502,129
2024-05-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−54.9K sh	$8.36	−$459K	2,561,894
2024-03-01	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+225K sh	—	—	225,226
2024-03-01	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+90.1K sh	—	—	90,090
2024-02-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−41.9K sh	$3.40	−$142K	2,616,812
2023-11-14	ACRVAcrivon Therapeutics, Inc.F Tax Payment	Director, President and CEO	FTax Payment	−239K sh	$5.08	−$1.21M	2,658,673
2023-08-21	ACRVAcrivon Therapeutics, Inc.A Award	Director, President and CEO	AAward	+494K sh	—	—	2,897,696
2023-05-31	ACRVAcrivon Therapeutics, Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+33.6K sh	$3.88	+$130K	2,403,702
2023-05-31	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−33.6K sh	—	—	90,855
2022-11-14	ACRVAcrivon Therapeutics, Inc.A Award	Director, President and CEO	AAward	+503K sh	—	—	2,310,007
2022-11-14	ACRVAcrivon Therapeutics, Inc.A Award	Director, President and CEO	AAward	+935K sh	—	—	1,806,588
2022-11-14	ACRVAcrivon Therapeutics, Inc.A Award	Director, President and CEO	AAward	+60.1K sh	—	—	2,370,097
2022-11-14	ACRVAcrivon Therapeutics, Inc.A Award	Director, President and CEO	AAward	+26.7K sh	—	—	320,705
2022-11-14	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+180K sh	—	—	180,269
2022-11-14	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+80.1K sh	—	—	80,120

Recent filings

Accepted (ET)
Aug 274
Blume-Jensen Peter0000905148-26-003968
SEC(opens sec.gov)
Aug 204
Blume-Jensen Peter0000905148-26-003836
SEC(opens sec.gov)
May 264
Blume-Jensen Peter0000905148-26-002652
SEC(opens sec.gov)
May 204
Blume-Jensen Peter0000905148-26-002549
SEC(opens sec.gov)
May 184
Blume-Jensen Peter0000905148-26-002498
SEC(opens sec.gov)
Mar 34
Blume-Jensen Peter0000905148-26-001115
SEC(opens sec.gov)
Feb 244
Blume-Jensen Peter0000905148-26-001010
SEC(opens sec.gov)
Feb 184
Blume-Jensen Peter0000905148-26-000934
SEC(opens sec.gov)
Jan 164
Blume-Jensen Peter0000905148-26-000226
SEC(opens sec.gov)
Nov 254
Blume-Jensen Peter0000905148-25-004179
SEC(opens sec.gov)
Nov 184
Blume-Jensen Peter0000905148-25-004127
SEC(opens sec.gov)
Aug 254
Blume-Jensen Peter0000905148-25-003121
SEC(opens sec.gov)
Aug 184
Blume-Jensen Peter0000905148-25-003039
SEC(opens sec.gov)

Companies

Acrivon Therapeutics, Inc.Director, President and CEOACRV

Address

C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100

WATERTOWN, MA, 02472